Casey Tansey Acquires 17,166 Shares of Mobia Medical (NASDAQ:MOBI) Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey bought 17,166 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were bought at an average cost of $11.85 per share, with a total value of $203,417.10. Following the transaction, the director directly owned 301,891 shares of the company’s stock, valued at approximately $3,577,408.35. This trade represents a 6.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Mobia Medical Stock Down 0.1%

NASDAQ:MOBI opened at $11.73 on Wednesday. The company has a 50 day moving average price of $12.40. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. Mobia Medical, Inc. has a 12 month low of $10.19 and a 12 month high of $15.29. The company has a market capitalization of $390.49 million and a price-to-earnings ratio of -0.61.

Mobia Medical (NASDAQ:MOBI) last posted its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The company had revenue of $13.51 million for the quarter. The firm’s revenue for the quarter was up 102.4% on a year-over-year basis. Research analysts predict that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wolfe Research assumed coverage on Mobia Medical in a research report on Tuesday, June 2nd. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. boosted their target price on shares of Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Wall Street Zen raised shares of Mobia Medical from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Weiss Ratings initiated coverage on shares of Mobia Medical in a research report on Wednesday, August 12th. They issued a “sell (e-)” rating on the stock. Finally, Bank of America initiated coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.